{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:31:09Z","timestamp":1788258669965,"version":"build-2803163510"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephrol. Dial. Transplant."],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1093\/ndt\/gfw286","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:48:45Z","timestamp":1470962925000},"page":"1771-1774","source":"Crossref","is-referenced-by-count":12,"title":["Con: STOP immunosuppression in IgA nephropathy"],"prefix":"10.1093","volume":"31","author":[{"given":"Thomas","family":"Rauen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Eitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fitzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"key":"2016110200282365000_31.11.1771.1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.12"},{"key":"2016110200282365000_31.11.1771.2","first-page":"284","article-title":"Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol","volume":"21","author":"Eitner","year":"2008","journal-title":"J Nephrol"},{"key":"2016110200282365000_31.11.1771.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463"},{"key":"2016110200282365000_31.11.1771.4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010117"},{"key":"2016110200282365000_31.11.1771.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00588.x"},{"key":"2016110200282365000_31.11.1771.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.06.013"},{"key":"2016110200282365000_31.11.1771.7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh974"},{"key":"2016110200282365000_31.11.1771.8","unstructured":"Lafayette RAC , Pietro A , Rovin BH et al . A randomized trial of rituximab in advanced IgA nephropathy. In: JASN Abstract Supplement for American Society of Nephrology Kidney Week, San Diego, CA, 2015. Abstract SA-PO1098. American Society of Nephrology, Washington DC, USA"},{"key":"2016110200282365000_31.11.1771.9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.168"},{"key":"2016110200282365000_31.11.1771.10","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.322"},{"key":"2016110200282365000_31.11.1771.11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012101017"},{"key":"2016110200282365000_31.11.1771.12","first-page":"337","article-title":"Histomorphometric correlates of renal failure in IgA nephropathy","volume":"49","author":"Vleming","year":"1998","journal-title":"Clin Nephrol"},{"key":"2016110200282365000_31.11.1771.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03563-6"},{"key":"2016110200282365000_31.11.1771.14","doi-asserted-by":"publisher","DOI":"10.1159\/000047764"},{"key":"2016110200282365000_31.11.1771.15","unstructured":"Floege J , Rauen T , Eitner F et al . Corticosteroid monotherapy versus combined immunosuppression in IgA nephropathy: insights from the STOP-IgAN trial. In: JASN Abstract Supplement for American Society of Nephrology Kidney Week, San Diego, CA, 2015. Abstract SA-PO1097. American Society of Nephrology, Washington DC, USA"},{"key":"2016110200282365000_31.11.1771.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.31"},{"key":"2016110200282365000_31.11.1771.17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.V82199","article-title":"Predicting renal outcome in IgA nephropathy","volume":"8","author":"Radford","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"2016110200282365000_31.11.1771.18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp356"},{"key":"2016110200282365000_31.11.1771.19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070697"},{"key":"2016110200282365000_31.11.1771.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.59"},{"key":"2016110200282365000_31.11.1771.21","unstructured":"Fellstrom BC , Coppo R , Feehally J et al . The NEFIGAN Trial: NEFECON, a novel targeted release formulation of budesonide, reduces proteinuria and stabilizes eGFR in IgA nephropathy patients at risk of ESRD. In: JASN Abstract Supplement for American Society of Nephrology Kidney Week, San Diego, CA, 2015. American Society of Nephrology, Washington DC, USA"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/31\/11\/1771\/7987361\/gfw286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T21:02:00Z","timestamp":1657054920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfw286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,2]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1093\/ndt\/gfw286"],"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw286","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]}}}